Gilead Sciences (GILD) Cash from Investing Activities (2009 - 2026)

Gilead Sciences has reported Cash from Investing Activities for 18 years, with the latest figure at $1.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 526.51% year-over-year to $1.8 billion; the trailing twelve-month figure through Mar 2026 stood at -$2.6 billion (down 57.39% YoY), and the FY2025 full-year result was -$4.8 billion, down 38.97% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $1.8 billion, up from -$1.8 billion in the prior quarter.
• The five-year high for Cash from Investing Activities was $1.8 billion in Q1 2026, with the low at -$2.2 billion in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$659.0 million across 5 years, with a median of -$483.0 million in 2023.
• Annual changes were most pronounced in 2025 — Cash from Investing Activities slumped 715.56% — and 2026, when it surged 526.51%.
• Gilead Sciences' Cash from Investing Activities stood at -$375.0 million in 2022, then tumbled by 93.87% to -$727.0 million in 2023, then soared by 69.05% to -$225.0 million in 2024, then tumbled by 715.56% to -$1.8 billion in 2025, then jumped by 196.46% to $1.8 billion in 2026.
• The last three Cash from Investing Activities figures came in at $1.8 billion (Q1 2026), -$1.8 billion (Q4 2025), and -$427.0 million (Q3 2025), per Business Quant data.